Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 7Phase 3 3Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Precancerous Conditions 1Breast Neoplasms 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × Fenretinide × Clear all
NCT00004154 2018-11-08

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

M.D. Anderson Cancer Center

Phase 3 Completed
111 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00003075 2018-10-24

Fenretinide in Treating Patients With Cervical Neoplasia

M.D. Anderson Cancer Center

Phase 3 Completed
39 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡